Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

BACKGROUND: High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC...

Full description

Saved in:
Bibliographic Details
Published in:Genome Med
Main Authors: Chalmers, Zachary R., Connelly, Caitlin F., Fabrizio, David, Gay, Laurie, Ali, Siraj M., Ennis, Riley, Schrock, Alexa, Campbell, Brittany, Shlien, Adam, Chmielecki, Juliann, Huang, Franklin, He, Yuting, Sun, James, Tabori, Uri, Kennedy, Mark, Lieber, Daniel S., Roels, Steven, White, Jared, Otto, Geoffrey A., Ross, Jeffrey S., Garraway, Levi, Miller, Vincent A., Stephens, Phillip J., Frampton, Garrett M.
Format: Artigo
Language:Inglês
Published: BioMed Central 2017
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395719/
https://ncbi.nlm.nih.gov/pubmed/28420421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-017-0424-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items